CClinicalTrials.gg
Status unknownNCT03268291Updated Aug 31, 2017

Communicational Program "Trust" to Improve Adherence to Medications

An interventional study of Standard outpatient observation and Communicational program "Trust" in Coronary Artery Disease, Myocardial Infarction and Cardiovascular Diseases, sponsored by Meshalkin Research Institute of Pathology of Circulation. Status unknown at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-31.

Sponsored by Meshalkin Research Institute of Pathology of Circulation · Not applicable, Interventional, and Health services research

The sponsor has not verified this record recently (last verified Aug 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The trial was designed in such a way as to show that the proposed program "Trust" increases the proportion of patients who adhere to therapy in the cohort of those with coronary heart disease for two years after successful revascularization by using thrombolytic or stenting of the coronary arteries against the background of myocardial infarction.

Read the detailed description

The "Trust" program includes a set of measures aimed at increasing the level of adherence to therapy in patients with myocardial infarction. Differences in adherence rates between patients enrolled in the program and patients undergoing standard outpatient care will be monitored during the study. The study will be conducted according to the clinical approbation protocol, the principles of good clinical practice (GCP) and regulatory requirements.

The developed program is based on the experience of international research studies and includes the following sections:

  • daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials;
  • service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators;
  • questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services.

Information motivating to remain adherence to the therapy is structured as follows:

A) greeting and presentation, a reminder of the necessity for therapy, with the support of the patient's Trust in prolonging the quality of life by regular use of medications; B) the explanation of the action of the medicine taking into account the peculiarities of ordinary consciousness, warning the patient of the most common mistakes in treatment; C) recommendations for changing lifestyle and explaining their need; D) a reminder of the possibility to contact the attending physician, emotional support and counseling.

The establishment of an information and counseling center will allow the patient to be supported throughout the time when the likelihood of giving up therapy and the risk of complications due to failure are most likely.

02

Conditions studied

  • Coronary Artery Disease
  • Myocardial Infarction
  • Cardiovascular Diseases

Keywords

  • Adherence to therapy
  • Myocardial Infarction
  • Coronary Artery Disease
  • Communicational program
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Signed informed consent
  • Recent acute myocardial infarction within the past 2 months
  • Successful revascularization via coronary stenting or thrombolysis

Exclusion criteria

Exclusion Criteria:

  • Concomitant cardiovascular disorders requiring surgical treatment
  • Coronary revascularization via CABG
  • Patient refused from participating
  • Patient is not available for communication within 2 months
04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Active comparator
    Standard outpatient observation

    Outpatient management according to Ministry of health standards

    Other: Standard outpatient observation

  • Experimental
    Communicational program "Trust"

    The developed program is based on the experience of international research studies and includes the following sections: * daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials; * service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators; * questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services.

    Behavioral: Communicational program "Trust"

Interventions

  • OtherStandard outpatient observation

    Outpatient management according to Ministry of health standards

  • BehavioralCommunicational program "Trust"

    The developed program is based on the experience of international research studies and includes the following sections: daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials; service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators; questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services.

05

What researchers measure

Primary outcomes

  1. Medication Adherence

    Adherence to every class of prescribed medications: Acetylsalicylic acid, P2Y12 receptor inhibitors, Beta-blockers, ACE inhibitors according to percent of medication taking days. Adherence above 80% will be satisfactory

    Time frame: During 1 year

06

Study locations

1 of 1 sites recruiting
  • State Research Institute of CIrculation Pathology
    Novosibirsk, 630055, Russian Federation
    • Evgeny Kretov, MD, PhD · Contact · sibvolna2005@yandex.ru
    • Evgeny Kretov, MD, PhD · Principal investigator
    • Aleksei Prokhorikhin, MD · Sub investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes — All the data

Supporting information: Study protocol, Csr

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03268291
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Responsible party
Sponsor
First posted
Aug 31, 2017
Start date
Mar 1, 2017
Primary completion
Dec 30, 2019 (estimated)
Completion
Dec 30, 2020 (estimated)
Last update
Aug 31, 2017

Study contacts

Aleksei Prokhorikhin
Contact
turbogold@list.ru
9137178040

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion